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Parkinson's disease
StriatumLevodopa is the most effective therapy for the motor deﬁcits of Parkinson's disease (PD), but long term
treatment leads to the development of L-DOPA-induced dyskinesia (LID). Our previous studies indicate en-
hanced excitability of striatal cholinergic interneurons (ChIs) in mice expressing LID and reduction of LID
when ChIs are selectively ablated. Recent gene expression analysis indicates that stimulatory H2 histamine
receptors are preferentially expressed on ChIs at high levels in the striatum, and we tested whether a
change in H2 receptor function might contribute to the elevated excitability in LID. Using two different
mouse models of PD (6-hydroxydopamine lesion and Pitx3ak/ak mutation), we chronically treated the
animals with either vehicle or L-DOPA to induce dyskinesia. Electrophysiological recordings indicate that
histamine H2 receptor-mediated excitation of striatal ChIs is enhanced inmice expressing LID. Additionally,
H2 receptor blockade by systemic administration of famotidine decreases behavioral LID expression in
dyskinetic animals. These ﬁndings suggest that ChIs undergo a pathological change in LID with respect to
histaminergic neurotransmission. The hypercholinergic striatum associated with LID may be dampened
by inhibition of H2 histaminergic neurotransmission. This study also provides a proof of principle of utiliz-
ing selective gene expression data for cell-type-speciﬁc modulation of neuronal activity.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Themajority ofmotor symptoms in Parkinson's disease (PD), includ-
ing bradykinesia, rigidity, and tremor are most effectively remedied by
3,4-dihydroxy-L-phenylalanine (L-DOPA), the biochemical precursor to
dopamine. An unfortunate consequence of long term L-DOPA treatment
is that within 4–6 years, more than half of patients develop L-DOPA-
induced dyskinesia (LID), which is characterized by potentiallyholinergic interneuron; LID, L-
uberomamillary nucleus; TRAP,
of Chicago, 5841 S. Maryland
Medical Center, 650 W. 168th
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ect.com).
. This is an open access article underdebilitating uncontrolled, hyperkinetic movements (Hauser et al.,
2007; Jenner, 2008). At present, a non-competitive antagonist of N-
methyl-D-aspartate (NMDA) glutamate receptors, amantadine, which
also has anticholinergic effect, is the only drug shown to alleviate LID
clinically (Fernandez, 2012). However, pharmacotherapy with amanta-
dine has limited efﬁcacy and potential adverse side effects (Thomas
et al., 2004;Wolf et al., 2010). Therefore, new approaches to LID therapy
are needed to alleviate LID symptomswithout interferingwith the anti-
parkinsonian effect of L-DOPA.
Unilateral 6-OHDA lesioned rodents are the most widely used ani-
mal models for PD and LID (Lundblad et al., 2004; Lundblad et al.,
2005; Pavon et al., 2006; Santini et al., 2009). While important aspects
of these conditions are present in these animals, this approach requires
intra-cranial infusion of the neurotoxin 6-OHDA, leading to variable
degrees of striatal DA denervation. These animals require extensive
post-operative care and the dose of L-DOPA used to induce behavioral
responses varieswidely (1mg/kgup to 25mg/kg), depending on the se-
verity of striatal DA denervation. In contrast, Pitx3ak/ak mice display the
selective loss of nigral dopamine neurons from birth due to a naturallythe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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2003). This is similar to mild PD with early onset of the disease. These
animals display bilateral striatal DA denervation and L-DOPA treatment
affects behavior on both sides of the body, while the unilateral 6-OHDA
lesion affects only the contralateral side. Thus, the bilateral vs. unilateral
response to L-DOPA results in the signiﬁcant phenotypic difference in
LID when treated with repetitive L-DOPA. In Pitx3ak/ak, LID engages
both sides of the body, inducing unique abnormal involuntary limb
movements with the body in a vertical position, while in 6-OHDA le-
sioned rodents, only one side of the body displays LID (Ding et al,
2007; Solis et al., 2015). The LID phenotype in Pitx3ak/ak is similar to
that in adult wild type mice treated with MPTP and a high dose of L-
DOPA in both biochemical and behavioral level (Nicholas, 2007) as
well as other genetic models of bilateral dopamine depletion (Chartoff
et al., 2001; Kim et al., 2000). While these animal models have advan-
tages and limitations, we have utilized both to optimally assess the
potential relevance of our observations to human PD patients.
Abnormal striatal cholinergic tone contributes to LID (Ding et al.,
2011). In the dorsal striatum, acetylcholine is synthesized and released
by a class of interneurons that are believed to be analogs of the ‘tonically
active neurons’ (TANs) described in primates, which are involved in as-
sociative learning (Aosaki et al., 1994, 1995; Kimura et al., 1984). In the
mouse, these cholinergic interneurons (ChIs) comprise between 1 and
2% of all striatal cells, but through their extensive arborization, they af-
fect the activity of both dopaminergic nerve terminals and the medium
spiny neurons that encode striatal output (Bolam et al., 1984; Calabresi
et al., 2000; Threlfell et al., 2012; Wilson et al., 1990). Dysfunction in
striatal cholinergic tone has been observed in movement disorders
including dystonia and Huntington's disease (Farrar et al., 2011;
Sciamanna et al., 2012), and our previous research implicates a role
for a change in ChI physiology in LID (Ding et al., 2011; Won et al.,
2014). In extracellular recordings of ChI ﬁring rate, enhanced baseline
excitability and hypersensitivity to dopamine are both associated with
LID inmousemodels of PD. Behavioral expression of LID is also associat-
ed with an increase in phosphorylated extracellular signal-regulated ki-
nase levels in ChIs. Both the altered ChI physiology and behavioral
expression of LID are dependent on the mitogen-activated protein ki-
nase signaling transduction pathway (Ding et al., 2011). Furthermore,
ablation of striatal ChIs reduces LID (Won et al., 2014). These data
indicate that modulation of striatal cholinergic tone may be a potential
target for LID therapy.
Inhibition of muscarinic receptors with the M1-selective antagonist,
dicyclomine (Giachetti, et al., 1986) can reduce the severity of LID (Ding
et al., 2011). As a therapy, blockingM1 receptors is prone to side effects
as these receptors arewidely expressed in the brain and affect a number
of networks and physiological processes (Smythies, 2005). The hista-
minergic systemmay be an alternative target in LID therapy, as changes
in histamine signaling have been implicated in the pathophysiology of
PD and LID. In post-mortem brain samples from patients with PD or ro-
dent PD models, extracellular histamine levels and the density of hista-
minergic ﬁbers are increased in several brain regions, including the
basal ganglia and substantia nigra pars compacta (Anichtchik et al.,
2000; Nowak et al., 2009; Rinne et al., 2002). The highly selective H2 re-
ceptor antagonist famotidine, when co-administered with L-DOPA in
MPTP-lesioned macaque monkeys, can reduce the severity of peak-
dose L-DOPA-induced chorea and can prolong the anti-parkinsonian
action of L-DOPA (Johnston et al., 2010). However, the mechanism for
this effect and potential therapeutic limits are unknown, as H3 agonists
that decrease choreic LID can also increase dystonic forms of LID
(Gomez-Ramirez et al., 2006).
In light of our previous studies implicating striatal ChI pathology in
LID, and considering reports of changes in histamine signaling associat-
ed with PD and LID, we data-mined the gene expression proﬁle of
striatal ChIs from the results of a study using translating ribosome afﬁn-
ity puriﬁcation in BAC transgenic mice (Doyle et al., 2008) and found a
relatively high and selective expression of H2 receptors. This resultprovided a strong rationale for targeting H2 receptors as a means to
modulate ChI activity and reduce LID in patients with PD. To test this
model, we used the selective H2 receptor antagonist, famotidine, to
evaluate the contribution of these receptors to ChI excitability, and to
examine the effects of H2 antagonism on behavioral measures of LID
in two mouse models of PD.
Materials and methods
Animals
All procedures were approved by the Institutional Animal Care and
Use Committee of the University of Chicago. Animals were housed in a
pathogen-free environment on a 12-hour light / dark cycle with unlim-
ited access to food and tap water.
Two animal models of PD were used for these experiments. One
was C57BL/6 mice unilaterally lesioned with 6-hydroxydopamine (6-
OHDA), as described previously (Won et al., 2014). And the second
was homozygous Pitx3ak/ak mice that lack nigrostriatal dopamine pro-
jections from birth, which we and others have also used previously
(Ding et al., 2007, 2011; Solis et al., 2015). Themain differences between
thesemodels are the timing of the dopamine loss (from birth vs after le-
sion) and the pattern of denervation, with the Pitx3ak/ak mice showing
bilateral DA denervation predominantly in the dorsal striatum, while
6-OHDA lesioned mice generally show unilateral striatal DA denerva-
tion across the entire striatum. LID induction required chronic treat-
ment with L-DOPA by daily injections, as outlined below. The L-DOPA
dosing for each model was determined empirically as that necessary
to induce dyskinetic behavior. Differences in dosing between these an-
imal models were due to differential denervation patterns and possible
developmental adaptations.
Electrophysiology
Parasagittal brain slices (250 μm) were taken from adult mice
pretreated with saline or L-DOPA as outlined in the behavioral testing
sections below. Mice were anesthetized with isoﬂurane (Baxter) and
then rapidly decapitated. Brains were removed and transferred into
ice-cold low-sodium, sucrose-artiﬁcial cerebrospinal ﬂuid (ACSF) con-
taining (mM): 200 Sucrose, 25 NaHCO3, 20 glucose, 10 ascorbic acid,
2.5 KCl, 2.5 CaCl2·2H2O, 1 MgCl2·6H2O, 1 NaH2PO4, saturated with
95% CO2/5% O2, pH 7.3. Separate parasaggital slices containing dorsolat-
eral striatumwere taken fromeachhemisphere using a vibratingmicro-
tome (VT1000S, Leica Biosystems) and transferred into a 32 °C
circulating bath with ACSF (125 NaCl, 25 NaHCO3, 20 glucose, 2.5 KCl,
2.5 CaCl2·2H2O, 1 MgCl2·6H2O, 1 NaH2PO4, 1 ascorbic acid, bubbled
continuously with 95% CO2/5% O2, pH 7.3). During recording, slices
were superfused with ACSF without ascorbate at a rate of 1.8–4 mL/
min at room temperature. All recordings were performed between
40 min and 6 h following slicing.
Slices were transferred to a recording chamber with a volume of
~1 mL and then visualized using an upright microscope (Axioskop,
Carl Zeiss) with a water immersion 40× objective (Carl Zeiss) and a
monochrome CCD camera (Hamamatsu). Recordings were performed
using borosilicate glass pipettes (Warner Instruments) pulled on a P-
97 Flaming/Brown micropipette puller (Sutter Instrument Company)
with pipette resistance of 2–5 MΩ, and ﬁlled with ﬁltered ACSF. Cell-
attached current clamp recordings were performed on ChIs that were
identiﬁed based on large cell diameter (N15 μm) and spontaneous action
potential ﬁring (0.1–7 Hz). Action potentials were measured using a
Multiclamp 700 A ampliﬁer with a 10 kHz low-pass Bessel ﬁlter and a
DigiData 1332A 16-bit data acquisition software sampling at 5 kHz and
recorded using Clampex 9.2 software (Axon Instruments). Action poten-
tial data were analyzed off-line using MiniAnalysis (Synaptosoft). Spike
amplitude thresholds were set to 20× baseline RMS noise levels, as de-
termined by the analysis software. Integrated spike area and rise-time
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of cell ﬁring. Frequency of ﬁring rate was determined in 10 second bins.
Data were expressed as mean ± SEM.
Histamine (1 μM; Sigma-Aldrich) was bath applied for 5 min. In an-
tagonist experiments, famotidine (1 μM; Envoy Therapeutics) dissolved
in either DMSO or acidiﬁed deionized water was pre-applied for 5 min
before histamine and antagonist co-application. The effect of histamine
on ﬁring rate was measured as the peak ﬁring rate in a 1 min time
window during time 1.5–8.5 min following onset of histamine bath ap-
plication. Flow rate of drug administration was matched to the ACSF
ﬂow rate (1.8–4 mL/min).Behavior test on unilateral 6-OHDA lesioned mice
Wild typemale, 7 month old C57BL/6 mice were unilaterally lesioned
with 6-hydroxydopamine (6-OHDA) as described previously (Won et al.,
2014). Brieﬂy, mice were anesthetized and put into a stereotaxic device.
Desipramine (25 mg/kg i.p., Sigma-Aldrich) was injected to protect
norepinephrine neurons. Thirty min later, 2 μL of 2 mg/ml 6-OHDA
(dissolved in 0.01% ascorbate in 0.9% saline, Sigma-Aldrich) was injected
into left medial forebrain bundle (coordinates: anteroposterior,
−1.3 mm; lateral, 1.3 mm; dorsoventral,−4.9 to−5.2 mm from the
skull surface) via a 28-gage stainless-steel cannula. Animalswere allowed
to recover for 4 weeks in their home cages before L-DOPA treatment.
Mice were then randomly divided into two groups, designated to
receive either chronic L-DOPA or chronic vehicle treatment. The chronic
L-DOPA group (n = 32) received L-DOPA methyl ester/benserazide
injections (2/12.5 mg/kg dissolved in 0.9% saline, i.p.) either once a
day or divided into two doses a day through the course the experiment.
The chronic vehicle group (n= 15) received benserazide (12.5 mg/kg)
only. Daily L-DOPA or vehicle injections continued for a total of 5–
9months. To conﬁrm the induction of dyskinesia, chronic L-DOPA treat-
ed mice underwent behavioral testing following a test dose of
2 mg/kg L-DOPA on days 1, 8, 22 and 36 after the initial L-DOPA treat-
ment. As in our previous studies, dyskinetic motor behavior was stron-
ger at later time points (Ding et al., 2007). On behavioral testing days,
animals received only the test dose of L-DOPA, but no maintenance
injection. After day 36, the test dose was increased to 3 mg/kg L-DOPA
and mouse behavior was videotaped for a span of 3 min every 20 min
during a 2 hour period. L-DOPA-induced limb and axial dyskinesia was
evaluated for 2 min at each 20 min interval by an observer blinded to
experimental conditions using a previously described rating scale
(Ding et al., 2011). Limb dyskinesia consists of abnormal, purposeless
hyperkinetic movement of the contralateral forelimb while axial dyski-
nesia is characterized by a twisting of the neck and upper torso towards
the side contralateral to the lesion. For experiments evaluating the ef-
fects of famotidine or dicyclomine on dyskinesia, the chronic L-DOPA
treated group was divided into three groups which were balanced
with respect to severity of dyskinesia. Group A received famotidine
(Envoy Therapeutics, dissolved in sterile water acidiﬁed with 1 mM
HCl and then adjusted to pH 6.5 with 1 mM NaOH, i.p.) at doses of 1,
3, and 10 mg/kg (increasing dosage every 2 days). Group B received
dicyclomine (Sigma-Aldrich, dissolved in 0.9% saline, i.p.) at 45 mg/kg.
Famotidine was administered 45 min, while dicyclomine was adminis-
tered 30 min prior to L-DOPA test dose (See Figs. 5A, 6A). Group C was
given saline to serve as a vehicle control for famotidine or dicyclomine.
The stepping test was videotaped and scored to assess forelimb
akinesia in chronic L-DOPA and chronic vehicle treated mice as de-
scribed previously (Ding et al., 2011). The front paws of the mice were
put on a treadmill as the belt moved forward for one full cycle while
the torso and hindpaws were held up by the experimenter. Each
mouse was tested in ﬁve nonconsecutive cycles. Stepping was scored
by an observer blinded to treatment conditions. The number of left
and right paw steps were counted for each of the 5 cycles and then av-
eraged. In chronic L-DOPA treated mice, the stepping test wasperformed before and 1 h following injection of 3 mg/kg L-DOPA.
Famotidine (1, 3, or 10 mg/kg) or saline (vehicle) was administered
45 min prior to the test dose of 3 mg/kg L-DOPA.
To test the in vivo brain concentration and pharmacokinetic time
course of famotidine inmice, we usedMetaQuantmicrodialysis tomea-
sure striatal levels following systemic administration.We found a signif-
icant increase in the levels of famotidine in the striatum of non-lesioned
mice after administration of 250 mg/kg i.p. The concentration of
famotidine in the dialysate from the striatum peaked at 225 nM at 60–
90 min. Given that the Kd of famotidine at the H2 receptor is 17 nM
(Hill, 1990), we used a range of doses between 1 and 50 mg/kg to
achieve maximal free striatal concentrations in the low nM range,
where famotidine is highly selective for H2. Injections were timed
such that the peak famotidine concentrations corresponded with the
peak L-DOPA-induced dyskinetic behavior. As illustrated in Figs. 5A
and 6A, the L-DOPA injections occurred 45min after famotidine admin-
istration. The doses used in the experiments did not produce sedation.
Behavior test on homozygous Pitx3ak/ak mice
Homozygous Pitx3ak/ak mice were obtained as described before
(Ding et al., 2007, 2011). Homozygous Pitx3ak/ak mice have a mutation
for retinal degradation (Pde6brd1), causing severely abnormal lens de-
velopment resulting in blindness (van den Munckhof et al., 2003;
Varnum and Stevens, 1968). They were identiﬁed by their small, closed
eyes, even late in development.
Pitx3ak/akmice (2–4months of age) were randomly divided into two
groups and matched with respect to age and gender. Group A received
daily injections of L-DOPA/benserazide (25/12.5 mg/kg dissolved in
0.9% saline, i.p.) b.i.d. (n = 21). Group B received vehicle (benserazide
12.5 mg/kg, i.p.) only (n= 20). Exposure to L-DOPA lasted 5–9months.
To assess dyskinetic behavior, Pitx3 ak/akmice were placed in a clear up-
right Plexiglas cylinder. The number of rearing events and duration of
abnormal paw movements were analyzed within a 2 min period
15 min following L-DOPA test dose (25 mg/kg). Abnormal paw move-
ments that were scored consisted of front paw dyskinesia, three paw
dyskinesia, and total dyskinesia, and each was analyzed separately.
Behavioral testing was performed and videotaped on days 1, 8, 22, 36,
and 40 to conﬁrm the onset of paw dyskinesia as described before
(Ding et al., 2007, 2011).
Group A Pitx3ak/ak mice were divided into three groups. The ﬁrst
group received saline (vehicle) 30 or 45 min prior to L-DOPA
(25 mg/kg) test dose (n = 7). The second group received famotidine
(2, 10, or 50 mg/kg, increasing in dosage every 2 days, i.p.) 45 min
prior to L-DOPA (25 mg/kg) test dose. The third group received
dicyclomine (15 or 45 mg/kg, increasing in dosage every 2 days, i.p.)
30 min prior to L-DOPA (25 mg/kg) test dose.
Data analysis
Data for behavioral and electrophysiological assessments are
expressed as mean ± SEM. All ﬁring rate data were normalized to
the average ﬁring rate across the six 10 s bins prior to any exposure
to drug. Electrophysiological analyses were performed using
MiniAnalysis 6.0.3 (Synaptosoft). Statistical analyses were per-
formed using SigmaStat, v.2.03 and graphed using SigmaPlot v.12.0.
An unpaired t-test was performed to determine statistical differences
between percent inhibition in electrophysiological measures, while
one or two way ANOVA was used for behavioral measures.
Results
Striatal cholinergic interneurons express histamine receptors
Drawing upon our previous results showing enhanced excitability of
striatal ChIs during LID along with the therapeutic effects of famotidine
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translating ribosome afﬁnity puriﬁcation (TRAP) (Doyle et al., 2008),
where the translatedmRNAof genetically deﬁned populations of neuro-
nal and glial cells, including striatal ChIs,were characterized bymicroar-
ray analysis. We compared the hybridization signals across the 24
different cell types from the probes that detect mRNAs encoding excit-
atory post-synaptic H1 and H2 histamine receptors. Both H1 and H2 re-
ceptor mRNAs were recovered with ribosomes puriﬁed from striatal
ChIs (Doyle et al., 2008), indicating that these receptors are expressed
on ChIs. These data are in agreement with previous observation that
histamine-induced depolarization of ChIs could be blocked largely by
H1 antagonists, but only minimally by an H2-selective antagonist (Bell
et al., 2000). The mRNA expression data support the observation that
H1 is highly expressed in ChIs. In contrast, the lower-abundance H2
mRNA shows the highest expression levels in ChIs compared to other
cell types, suggesting a more selective target compared to the widely
expressed H1 receptor (Fig. 1). Therefore, H2 antagonistsmay selective-
ly reduce the sensitivity of ChIs to histaminewhile minimizing undesir-
able effects on other histamine dependent functions, such as sleep
regulation or feeding behavior (Nuutinen and Panula, 2010).
Histamine increases excitability of dorsolateral striatal cholinergic
interneurons
We assessed the effects of histamine on the excitability of rostral
dorsolateral striatal ChIs in parasagittal slices taken from two differentFig. 1. Expression of excitatory post-synaptic histamine receptors in striatal ChIs. Striatal ChIs ex
(Doyle et al., 2008)was searched to determinewhich histamine receptormRNAs are co-immun
tyltransferase promoter exclusively in ChIs within the striatum. The mean ﬂuorescent inten
(1423639_at)] in ChIs were 359.5 and 85.0, indicating both mRNAs were co-puriﬁed with the
cell types. Histamine H1 (Hrh1) mRNA was recovered with tagged ribosomes in several cell
the highest hybridization signal in striatal ChIs.mouse models of PD: unilateral 6-OHDA lesion and Pitx3ak/ak mutation.
All mice were subjected to daily injections of either L-DOPA or vehicle
for 5–9 months. Cell-attached current clamp recordings were per-
formed on ChIs that were identiﬁed based on cell morphology (cell
diameter N 15 μm) and electrophysiological characteristics (spontane-
ous action potential ﬁring rate between 0.1 and 7 Hz) (Kawaguchi,
1993). All ChIs were located in the rostral half of the dorsolateral stria-
tum (Fig. 2A). Our control recordings were conducted in the unlesioned
hemisphere of 6-OHDA lesioned animals following chronic vehicle
treatment. Bath application of histamine (1 μM) increased spontaneous
action potential ﬁring in these neurons (411% ± 142% of baseline, n =
6). This increase in excitation was reversed upon washout with ACSF
(Fig. 2B, C). These data are consistentwith previous reports demonstrat-
ing that bath application of histamine induces excitatory currents in
whole cell voltage clamp recordings, and depolarization accompanied
by action potential ﬁring in current clamp recordings from previously
silent rat striatal ChIs (Bell et al., 2000).
Chronic L-DOPA treatment enhances histamine H2 effect on cholinergic in-
terneuron excitability in 6-OHDA lesioned mice
Following unilateral 6-OHDA lesion, chronic L-DOPA treatment
induces LID-like behaviors, and only animals that demonstrated LID be-
haviorswere used for electrophysiology experiments (Ding et al., 2007).
In the chronic vehicle treated group, only mice exhibiting a signiﬁcant
unilateral stepping deﬁcit (indicative of dopamine deﬁciency) (Changpress both histamineH1 and histamine H2 receptors. Published BAC-TRAPmicroarray data
oprecipitatedwith eGFP-tagged ribosomes expressed under the control of the choline ace-
sities of Affymetrix probesets corresponding to H1 [Hrh1 (1438494_at)] and H2 [Hrh2
ribosomes. Histamine H1 and H2 receptor mRNA levels were compared across multiple
types at levels the same or higher than in striatal ChIs. Histamine H2 (Hrh2) mRNA had
Fig. 2. Histamine induced excitation in control dorsolateral striatal cholinergic interneu-
rons. (A) All cells analyzed for the following experiments were located in the dorsal, later-
al, and rostral halves of the striatum, indicated by the striped area outlined above. Lateral
half was deﬁned by the coordinates 2.75 and 1.75 mm from midline. This diagram also
represents the parasagittal slice orientation and approximate amount of brain tissue col-
lected at the time of recording. (B) Representative cell-attached current clamp traces
from ChIs located in the unlesioned hemisphere of 6-OHDA lesioned animals showing
spontaneous action potential ﬁring at baseline. Firing rate increases upon exposure to
bath application of 1 μMhistamine. Return to ACSF superfusion causes ﬁring rate to return
to baseline levels. Vertical scale bar: 1mV. Horizontal scale bar: 1 s. (C) 1 μMhistamine in-
duces a reversible 4.11 ± 1.42 fold increase in action potential ﬁring rate. Histamine in-
duced increase is represented as fold change difference compared to the average ﬁring
rate in the min prior to bath application. (n = 6. Error bars represent ± SEM).
Fig. 3. H2 antagonism is more effective at blocking the histamine induced increase in ChI
ﬁring in dyskinetic 6-OHDA lesioned mice. (A) 1 μM histamine increases action potential
ﬁring rate among ChIs located in the lesioned hemisphere of 6-OHDA lesioned mice,
both chronically treated with vehicle and with L-DOPA. A1 shows sample traces (Scale:
1 mV, 1 s for A1 and B1). A2 shows a histogram of average ﬁring rates. (Vehicle: n = 6;
L-DOPA: n=8). (B) In chronic vehicle-treated animals, pre-application of 1 μMfamotidine
had no effect on the histamine induced increase inﬁring rate. In dyskinetic L-DOPA treated
animals however, 1 μM famotidine inhibited the histamine induced increase in ChI ﬁring.
(Vehicle: n = 16; L-DOPA: n = 10. Data were analyzed using Student's t-test. * p b 0.05).
(C) Summary data illustrating that pre-application of 1 μM famotidine inhibits the hista-
mine induced increase in action potential ﬁring in chronic L-DOPA treated animals but
not vehicle-treated animals. Dotted line indicates peak histamine induced increase in
ﬁring rate, normalized for each treatment group. Bars represent percent change of the
histamine response while in the presence of famotidine (* p b 0.05 between treatment
groups. Error bars represent ± SEM). (D) Pre-application of both H1 and H2 receptor an-
tagonists completely occlude the excitatory effects of histamine. (n = 3) (E) Famotidine
blocked the histamine induced excitation in dyskinetic mice in the presence of synaptic
excitatory (DNQX, APV) and inhibitory (GABA) antagonists (Vehicle: n = 7; L-DOPA:
n = 5. * p b 0.05 between treatment groups).
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Fig. 4. H2 antagonism is more effective at blocking the histamine induced increase in ChI
ﬁring in dyskinetic Pitx3ak/akmice. (A) 1 μMhistamine increases action potential ﬁring rate
among ChIs located in both hemispheres of Pitx3ak/ak mice, both chronically treated with
vehicle and with L-DOPA. (Vehicle: n = 8; L-DOPA: n = 9). (B) In nondyskinetic, chronic
vehicle-treated animals, pre-application of 1 μMfamotidinehad no effect on the histamine
induced increase in ﬁring rate. In dyskinetic L-DOPA treated animals however, 1 μM
72 S.A.O. Lim et al. / Neurobiology of Disease 76 (2015) 67–76et al., 1999) were used for electrophysiology. We found a similar effect
of histamine (1 μM) on the excitability of ChIs in brain slices from the
lesioned hemisphere of either chronic vehicle treated mice (633% ±
167% of baseline, n = 6) or dyskinetic chronic L-DOPA treated animals
(415% ± 147% of baseline, n = 8; Fig. 3A. Data were analyzed using
Student's t-test. t(12) = 0.95, p N 0.05).
To evaluate the contribution of H2 receptors to the excitatory effects
of histamine, slices were pretreated with famotidine (1 μM) for 5 min
before histamine (1 μM) and famotidine co-application. Famotidine
alone did not produce a signiﬁcant difference in the ﬁring rate com-
pared to baseline. In slices from animals that were chronically treated
with L-DOPA, the co-application of famotidine and histamine resulted
in less histamine mediated excitation than histamine alone, but not in
slices from the chronic vehicle treated group (Fig. 3B; t(24) = 2.24,
p b 0.05). In vehicle treated animals, famotidine showed a relatively
weak inhibitory effect (75.3% ± 10.7% of histamine response), while
ChIs in slices from dyskinetic animals displayed signiﬁcant famotidine
inhibition (44.3% ± 7.1% of histamine response; Fig. 3C; t(23) = 2.16,
p b 0.05). Together, these data indicate that H2 receptors contribute
more strongly to ChI excitation in mice expressing LID compared to
chronic vehicle treated animals.
The histamine mediated excitation observed in the presence of
famotidine can be attributed to activation of H1 receptors. This is sup-
ported by recordings where co-application of famotidine with the H1R
antagonist triprolidine completely inhibited histamine induced excita-
tion (Fig. 3D). The famotidine alone effects suggest that H1 receptors
are predominantly responsible for the excitatory effects of histamine
on ChIs from vehicle treated animals (Fig. 1). It is notable that H1 recep-
tors are also activated at lower histamine concentrations (Munakata
and Akaike, 1994). In tissue slices from chronic L-DOPA-treated animals,
both H1 and H2 receptors contribute to histamine-induced excitation,
but the relative contribution of H2 receptors to this phenomenon is sig-
niﬁcantly enhanced relative to ChIs from vehicle treated animals. Co-
application of famotidine with the H1R antagonist triprolidine signiﬁ-
cantly blocks histamine induced excitation (145% ± 40% of baseline;
Fig. 3D, n = 3). As a result, we conclude that histamine increases cell
ﬁring by activation of both H1 and H2 receptors.
To assess the possible contribution of glutamatergic and/or GABA-
ergic transmission to histamine excitation of ChIs, recordings were con-
ducted in the presence of DNQX (10 μM) and APV (50 μM) to block
AMPA and NMDA glutamate receptors, respectively, as well as
bicuculline (20 μM) to block GABAA receptors. Under these conditions,
we observed an enhanced H2mediated component of histamine excita-
tion in the dyskinetic chronic L-DOPA treated animals (Fig. 3E; t(10) =
1.328, p b 0.05), indicating that the LID-related H2 excitation of these
neurons is mediated by direct activation of ChIs rather than by indirect
presynaptic effects. The magnitude of the histamine excitation is lower
than that seen without blockers of glutamate and GABA transmission.
This could be due to loss of tonic glutamate excitation reported previ-
ously (Feng et al., 2014), or a decrease in the impact of excitatory inputs
from other ChIs, as the glutamate co-released at those inputs would not
contribute to increased ﬁring rates (Gras et al., 2008; Nelson et al.,
2014).famotidine inhibited the histamine induced increase in ChI ﬁring. (Vehicle: n = 10; L-
DOPA: n = 8. Data were analyzed using a two-tailed Student's t-test. * p b 0.05).
(C) Summary data illustrating that pre-application of 1 μM famotidine inhibits the hista-
mine induced increase in action potential ﬁring in chronic L-DOPA treated dyskinetic ani-
mals but not vehicle-treated animals. Dotted line indicates peak histamine induced
increase inﬁring rate, normalized for each treatment group. Bars represent percent change
of the histamine response while in the presence of famotidine. (* p b 0.05 between two
treatment groups. Error bars represent ± SEM).Chronic L-DOPA treatment enhances histamine H2 effect on cholinergic in-
terneuron excitability in Pitx3ak/ak mice
To further examine the role of H2 receptors in LID, we repeated the
electrophysiological tests using Pitx3ak/ak (aphakia) mice. As with the 6-
OHDA lesioned mice, the Pitx3ak/ak mice were chronically treated with
vehicle or L-DOPA (see Methods). In dorsolateral ChIs from both striatal
hemispheres of Pitx3ak/ak mice, histamine alone induced an increase in
tonic ﬁring in both chronic vehicle treated (376% ± 101% of baseline,
n = 8) and dyskinetic chronic L-DOPA treated animals (356% ± 108%
of baseline, n = 9; Fig. 4A; t(15) =−0.16, p N 0.05).Famotidine application alone did not signiﬁcantly alter the ﬁring
rate compared to baseline. As seen in 6-OHDA lesioned animals, co-
application of famotidine with histamine revealed a differential degree
of histamine mediated excitation depending on treatment group
(Fig. 4B; t(16)= 2.3, p b 0.05). The inhibition of the histamine response
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(54.3%± 9.8%) compared to slices from chronic vehicle treated animals
(111.5% ± 18.4%; Fig. 4C; t(16) = 2.54, p b 0.05). Together, the data
from both PDmodel animals indicate that the H2 receptor contribution
to histamine mediated excitation of ChIs is stronger in chronic L-DOPA-
treated relative to vehicle-treated mice.
Famotidine or dicyclomine decreases behavioral expression of LID in
6-OHDA lesioned mice
We then tested whether famotidine could reduce the LID behaviors
associated with chronic L-DOPA treatment (see Methods). Mice re-
ceived an i.p. injection of famotidine 45 min prior to L-DOPA test dose.
The peak in striatal famotidine level occurs 60–90 min after injection.
The injection time course was designed such that the peak famotidine
level correlates with the peak L-DOPA-induced dyskinetic behavior
(Fig. 5A). Famotidine injections at the highest dose tested (10 mg/kg)Fig. 5. Famotidine decreases L-DOPA-induced dyskinesia in 6-OHDA lesioned mice. (A) Timelin
treated 6-OHDA lesioned mice were pretreated with famotidine 45 min or dicyclomine 30 m
famotidine or dicyclomine prior to L-DOPA. Behavioral tests were performed 60 min after L-DO
dyskinesia. (B) Stepping test for 6-OHDA mice pretreated with vehicle or famotidine (10 mg/k
pretreatment. (n= 10 animals in each group. Data were analyzedwith a one-way ANOVA on ra
(C), axial dyskinesia (D), and limb dyskinesia (E) in 6-OHDA lesioned mice chronically treated
dyskinesia in the 6-OHDA lesioned mice. (DC — dicyclomine. DC: n = 16, Saline: n = 32, Fam
ANOVA. Data from panel F was analyzed with Kruskal–Wallis ANOVA on Ranks. * p b 0.05 comdid not alter the L-DOPA-induced improvement of locomotion, or relief
of akinesia in the 6-OHDA lesioned mice, as measured in a forelimb
stepping test (Fig. 5B; n = 10 in each group. Data were analyzed using
a one-way ANOVA on ranks. F(2, 38) = 71.012, p b 0.05).
A test dose of 3mg/kg L-DOPAwas given to all mice prior to LID test-
ing. Assessment of ‘total dyskinesia’ includedmeasurement of both axial
dyskinesia (twisting of the neck and upper body towards the side con-
tralateral to the lesion) and limb dyskinesia (purposeless hyperkinetic
movement of the contralateral forelimb). The effects of famotidine on
LID were compared with that of dicyclomine, a muscarinic antagonist
that is known to attenuate LID associated behaviors (Ding et al., 2011).
Mice receiving famotidine exhibited signiﬁcantly less severe L-
DOPA-induced total dyskinesia. The higher doses (3 and 10 mg/kg)
showed a decrease at 20, 40, 60 and 80 min following L-DOPA injection,
while 1mg/kg showed a decrease only at the 60min timepoint (Fig. 5C;
Saline: n = 32, famotidine 1 mg/kg: n = 9, 3 mg/kg: n = 9, 10 mg/kg:
n = 16; dicyclomine 45 mg/kg: n = 16. Data were analyzed using ae for the drug treatment and behavioral tests on 6-OHDA lesioned mice. Chronic L-DOPA
in prior to L-DOPA. Control groups were injected with saline with the same interval as
PA injection for stepping test, and every 20 min for a total of 120 min for assessment of
g) 45 min prior to L-DOPA (3 mg/kg). L-DOPA improved unilateral akinesia regardless of
nks. * p b 0.05). Famotidine or dicyclomine decreased the L-DOPA-induced total dyskinesia
with L-DOPA. (F) Summary of the effect of famotidine or dicyclomine on L-DOPA-induced
1 mg/kg: n = 9, 3 mg/kg: n = 9, 10 mg/kg: n = 16. Data were analyzed with a two-way
pared with saline treated group. Error bars represent ± SEM).
Fig. 6. Famotidine decreases L-DOPA-induced dyskinesia in Pitx3ak/ak mice. (A) Timeline
for the drug treatment and behavioral tests on Pitx3ak/ak mice. Chronic L-DOPA
(25mg/kg) treated Pitx3ak/akmicewere pretreatedwith famotidine 45min or dicyclomine
30minprior to L-DOPA. Control groupswere injectedwith salinewith the same interval as
famotidine or dicyclomine prior to L-DOPA. Behavioral tests were performed 15 min after
L-DOPA injection to quantify duration of three-paw dyskinesia (B) and front paw dyskine-
sia (C) (DC— dicyclomine. n = 7 animals in each group. Data were analyzed with a one-
way ANOVA. * p b 0.05 compared with saline treated group. Error bars represent ± SEM).
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similar to those seen following dicyclomine treatment (45 mg/kg)
(Fig. 5C). Summing dyskinesia scores over the entire time frame of LID
testing from 0 to 120 min revealed that the higher doses of famotidine
(3 and 10 mg/kg) or dicyclomine (45 mg/kg) signiﬁcantly reduced
total dyskinetic behavior (Fig. 5F).
A signiﬁcant decrease in axial dyskinesia was observed following
pretreatment. The high dose famotidine (10 mg/kg) showed a decrease
at 40, 60, and 80min, while 1 and 3mg/kg showed a decrease at 60min
and 80min (Fig. 5D; F(3, 24)= 4.755, p b 0.05). Sumof axial dyskinesia
over the entire time course was decreased following pretreatment with
famotidine (3 and 10 mg/kg, Fig. 5F). Dicyclomine (45 mg/kg) signiﬁ-
cantly decreased the L-DOPA-induced axial dyskinesia at 20, 40, and
60 min, as well as the sum of axial scores across the time course of LID
testing (Fig. 5D, F).
Limb dyskinesia is decreased inmice receiving famotidine (3mg/kg,
10 mg/kg) at 20, 40, and 60 min (Fig. 5E; F(3, 24) = 6.373, p b 0.05)
compared to mice receiving saline. Sum of the limb dyskinesia across
the time course was also decreased following famotidine treatment
(Fig. 5F). The antidyskinetic effect of high dose famotidine (10 mg/kg)
was comparable to the dicyclomine (45 mg/kg) mediated decrease in
dyskinesia.
Together these data show that famotidine treatment reduced peak
LID expression and its duration, with the strongest effects seen at the
higher doses. The greatest fractional effects of the highest famotidine
doses were seen in limb dyskinesia, with greater than 50% reduction
in the sum L-DOPA effect. Axial dyskinesia behaviors were more
pronounced, and were less sensitive to the famotidine treatment —
however, the famotidine induced improvement of LID was similar to
that seen with dicyclomine treatment.
Famotidine or dicyclomine decreases behavioral expression of LID in Pitx3-
ak/ak mice
Behavioral testing was also carried out on chronic L-DOPA treated
Pitx3ak/ak mice that expressed dyskinesia. Animals were pretreated
with famotidine, dicyclomine or saline prior to L-DOPA test dose
(25 mg/kg) and behavioral testing (Fig. 6A; n = 7 in each group). Two
types of abnormal pawmovements were analyzed: three-paw dyskine-
sia and front paw dyskinesia. Since three-paw dyskinesia is observed
after higher doses of L-DOPA and with longer exposure to L-DOPA, we
believe it represents a more severe form of dyskinesia (Ding et al.,
2007). Famotidine (50 mg/kg) signiﬁcantly reduced three-paw dyski-
nesia, an effect mimicked by dicyclomine (Fig. 6B; Data were analyzed
using a one-way ANOVA. Famotidine, F(3, 12) = 3.478, p b 0.05.
Dicyclomine, F(3, 12) = 17.633, p b 0.05). As the three-paw form of
dyskinesia diminished, the animals displayed a trend towards an
increase in front paw dyskinesia, whichwas also seenwith dicyclomine
(Fig. 6C; Famotidine, F(3, 12) = 2.061. Dicyclomine, F(3, 12) = 10.797.
p b 0.05). Taken together, the pattern of dyskinesia in chronic L-DOPA
treated Pitx3ak/ak mice shifts from three-paw to front paw in response
to treatment with famotidine or dicyclomine, indicating that both
drugs decrease the severity of dyskinesia.
Discussion
Our results support the idea that H2 antagonists can selectively
modulate the hyperactive ChI and may decrease the expression of dys-
kinetic behavior following chronic L-DOPA treatment. These studies
were motivated by results of mining BAC-TRAP gene expression data,
which suggested that ChIs express histamine H2 receptor mRNA at
higher levels than other cell types. Using two PD mouse models, 6-
OHDA lesion and Pitx3ak/ak, we found that histamine induced a strong
increase in ﬁring of ChIs in the dorsolateral striatum. After chronic L-
DOPA treatment to induce LID, we found that H2 receptors contributed
much more profoundly to histamine-induced excitation relative tovehicle-treated controls. Consistent with these data, we found that
systemic administration of the H2 antagonist famotidine decreased
the behavioral expression of dyskinesia following a test dose of L-DOPA.
These data suggest that changes in H2 receptor signaling in dorsolat-
eral striatal ChIs contribute to LID. We previously demonstrated that
these neurons display a stronger excitatory response to dopamine in
LID (Ding et al., 2011). Here, we extend those ﬁndings to show that
H2 histamine receptor effects on ChIs are enhanced in animals that
display LID after chronic L-DOPA treatment. We utilized two different
complementary models of mouse dyskinesia to demonstrate the effects
of H2 antagonist. The H2 antagonist famotidine decreased LID dramati-
cally in a 6-OHDA unilateral lesionmodel of PD. In Pitx3ak/akmice, a high
dose of famotidine was found to shift the behavior from three-paw
dyskinesia to the less severe front paw dyskinesia. Since front paw
dyskinesia develops early in L-DOPA treatment and at lower doses
compared to three-pawdyskinesia, these data show that famotidine de-
creases the severity of LID in Pitx3ak/ak mice. Additionally, the Pitx3ak/ak
mouse model exhibits less striatal dopamine depletion compared to
the 6-OHDA lesion (Conti et al., 2014; Hwang et al., 2003) and require
a higher dose of L-DOPA to induce behavioral response (Espadas et al.,
2012; Hwang et al., 2005). This could explain why a higher dose of
famotidine was necessary to decrease LID in Pitx3ak/ak mice than mice
with 6-OHDA lesion. The data from both models support the idea that
H2 antagonists may be a therapeutic adjunct in alleviating the
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similar dose range as our study.
Acetylcholine activates both nicotinic and muscarinic receptors, and
blocking either of these receptor classes reduces LID. Dyskinetic 6-
OHDA lesioned rats chronically treated with the non-selective neuronal
nicotinic receptor antagonist mecamylamine display a dramatic reduc-
tion in abnormal involuntary movements (Bordia et al., 2010). Chronic
nicotine administration also decreases abnormal involuntary move-
ments, which is likely due to receptor desensitization (Bordia et al.,
2008). Additionally, the anti-muscarinic compound, dicyclomine, allevi-
ates severity of dyskinesia in chronic L-DOPA treated Pitx3ak/akmice and
in 6-OHDA lesioned mice (Ding et al., 2011). In a small cohort of
humans, co-administration of L-DOPA with the anticholinergic
etybenzatropine decreased the severity of end-of-dose dyskinesia, and
also increased the duration of action of L-DOPA (Pourcher et al., 1989)
although older studies have noted worsening of LID by anticholinergics
(Birket-Smith, 1974). Collectively, these conﬂicting results may indicate
different contributions between pharmacological anticholinergic ma-
nipulations that targetmany cell types versus cell type-speciﬁcmodula-
tion of ChI to the expression of LID.
Histaminergic neurons in the tuberomamillary nucleus (TMN) are
tonically active cells that send projections to the striatum (Haas et al.,
2008; Köhler et al., 1985). Dopamine directly excites TMN neurons via
both the dopamine D1 and D2 receptors (Yanovsky et al., 2011),
which likely increases histamine release in the striatum. Histamine
then activates excitatory H1 and H2 receptors on ChIs to increase cell
excitability, and consequently, acetylcholine release in the striatum.
H1 receptors couple to the G-protein Gq/11 to activate PLC, whereas H2
receptors stimulate cAMP production by Gs activation of adenylyl
cyclase (Haas et al., 2008). Ultimately, activation of either H1 or H2
receptors increase striatal ChI excitability by closure of K+ channels
(Munakata and Akaike, 1994). This explains how L-DOPA, following
enzymatic conversion into dopamine, increases striatal cholinergic
tone via histaminergic signaling.
Compared to the H2 receptor, the H1 receptor is expressed at much
higher levels (Fig. 1), and also exhibits a higher afﬁnity for histamine.
Therefore, we expect that in the naïve animal, histamine induced exci-
tation of ChIs will occur predominantly via activation of H1 receptors
with minimal contribution from H2. In line with this prediction, Bell
and coworkers observe only slight depolarization in naive rats following
H2 activation, but robust action potential ﬁring with H1 activation (Bell
et al., 2000). However, dyskinesia from chronic L-DOPA treatment may
induce a shift in the signaling pathway away from H1 and towards H2.
This accounts for the robust H1-mediated excitation in vehicle-treated
mice, but a strong contribution of H2 in dyskinetic mice (Figs. 3 and
4). This is a functional effect thatmay not necessarily accompany chang-
es in H2 receptor numbers (Martinez-Mir et al., 1993).
Histamine modulates excitability of striatal medium spiny neurons,
primarily through H3 receptor-mediated suppression of presynaptic
glutamate and GABA inputs (Prast et al., 1999; Ellender et al., 2011).
In contrast, histamine excitation of striatal ChIs appears to be pre-
dominantly through activation of somatic H1 and H2 receptors, as
shown by the blockade of histamine excitation with H1 and H2 in-
hibitors (Fig. 3D). In addition, the presynaptic H3 receptors are gen-
erally inhibitory and suppress neurotransmitter release. In the slice
preparation, inhibitors of either GABAA or glutamate receptors have
no effect on the ﬁring rate of ChIs (Bennett andWilson, 1999). In our
recordings, ChI ﬁring rate was unaffected by bath application of
bicuculline (10 μM; data not shown). Thus, we conclude that hista-
mine excitation of ChIs occurs through direct activation of these
neurons, and that the LID-associated increases in the H2 response
occurs speciﬁcally on these neurons.
Our study is a powerful example of the utility of data mining gene
expression studies to identify neuron-speciﬁc expression patterns for
therapeutic discovery. Our results suggest that H2 antagonists may pro-
vide a novel tool to modulate the hyperactivity of striatal cholinergicneurons. A better understanding of the contribution of cholinergic and
histaminergic signaling to striatal physiology, particularly in the context
of LID andmore selective and potentmodulators of ChImay lead to new,
more effective pharmacotherapies for basal ganglia disorders involving
hyperactive ChIs.
Conclusions
Although L-DOPA is themost effective therapy to alleviate PD, chron-
ic treatment often leads to the development of debilitating dyskinesia.
This dyskinesia is associated with excessive ChI activity within the stri-
atum. Here, we report an increase in the H2 receptor component of his-
tamine mediated excitation of ChIs associated with LID. The
behavioral expression of dyskinesia is decreased in the presence of an
H2 receptor antagonist in two differentmousemodels of LID. Collective-
ly, these ﬁndings indicate that further exploration of selective gene ex-
pression and better H2 antagonists may provide a useful therapeutic
tool to modulate ChI activity, which may have implications for condi-
tions such as LID in PD and dystonia.
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